March 2013 – QPS360 Newsletter – Third Edition ›   Corporate The Hamner Institutes for Health Sciences Announces Partnership with QPS Holdings, LLC QPS Announces the Acquisition of Miami Research Associates Amorfix and QPS to Collaborate on Alzheimer's Disease Project ›  Neuropharmacology In Vitro Models of Alzheimer’s Disease ›   DMPK Ex Vivo Protein Binding Data is Needed during Proof-of-Concept Stage ›   Bioanalysis The Bioanalysis of Antibody Drug Conjugates ›   Translational Medicine Validation of a Gyrolab Assay for Quantification of Rituximab in Human Serum ›   Early Stage Clinical Serial CSF Sampling over a Period of 30 h via an Indwelling Spinal Catheter in Healthy Volunteers: Headache, Back Pain, Tolerability and Measured Acetylcholine Profile ›   Phase II - IV Clinical Imaging Methods for Alzheimer’s Disease QPS provides essential preclinical and clinical research services to help pharmaceutical and biotechnology companies around the globe accelerate the discovery and development of drugs to prevent, treat and cure brain diseases, with a special focus on age-related neurodegenerative disorders such as Alzheimer’s and Parkinson’s Disease.

Dear Industry Colleagues, I hope you’ve all had a great start to 2013. On behalf of QPS’ management team, we would like to express our sincere appreciation to all of our clients, vendors, and employees for making 2012 successful for QPS. We are sincerely thankful...